Stocks

Keros Therapeutics KROS

Health care sectorNasdaq

What to see in Keros Therapeutics now

Is Wall Street adding or cutting?−19

132 13F filers hold it · −19 against the quarter before · shares held +7.4%

Holdings of 06/30
Who bought more than 5%?8.4%

BlackRock holds 8.4% · −1.7pp on the report before

Filed 07/29
What comes next?10/13 (Tue)

10/13 estimated earnings

Due 10/13

Company

Exchange
Nasdaq
Industry
Pharmaceutical Preparations
Headquarters
Lexington, Massachusetts
Fiscal year end
12/31
Next earnings
10/13, estimated
  • 132 13F filers hold it · −19 against the quarter before · shares held +7.4%Holdings of 06/30
  • BlackRock holds 8.4% · −1.7pp on the report beforeFiled 07/29

Funds

13F filers: 132 · −19 since the quarter before · 06/30 holdings

Famous funds that held Keros Therapeutics in their latest 13F report.

FundValueSince the quarter before
Mirae Asset Global ETFS HoldingsKeros Therapeutics KROS · 06/30 holdings$91.1KNo quarter before
Mirae Asset Global InvestmentsKeros Therapeutics KROS · 06/30 holdings$9,470Trimmed −44.3%
All tracked funds

5% stakes

Holder
BlackRock07/298.4%1,671,343 sh−1.7pp
BlackRock Portfolio Management07/175.7%1,122,874 shFirst report
Nantahala Capital Management05/156.9%1,360,419 shFirst report
BlackRock04/0710.1%1,990,842 shFirst report
Vanguard Group03/270%0 sh−5.0pp
ExodusPoint Capital Management02/170.04%13,360 sh−6.3pp
Madison Avenue Partners02/172.7%823,707 sh−3.7pp
Tang Capital Management02/170%0 sh−7.9pp
D. E. Shaw02/173.9%756,156 sh−1.2pp
Vanguard Group01/305%1,525,355 sh−1.3pp
ExodusPoint Capital Management25/11/186.3%1,907,899 shFirst report
D. E. Shaw25/10/275.1%1,545,948 shFirst report
Tang Capital Management25/10/227.9%2,418,984 shFirst report
Pontifax Management 4 G.P.25/10/160%0 sh−11.8pp
ADAR1 Capital Management25/10/150%0 sh−13.3pp
ADAR1 Capital Management25/08/2113.27%5,389,264 sh+0.0pp
Madison Avenue Partners25/05/146.4%2,614,402 shFirst report
ADAR1 Capital Management25/05/1213.27%5,390,964 sh+0.0pp
ADAR1 Capital Management25/05/0813.27%5,390,964 sh−0.0pp
Chase & Co Jpmorgan25/05/050.2%113,803 sh−6.1pp
All 5% stake reports on Keros Therapeutics

26-week trading